Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VOR33 in High-Risk AML and MDS Post-HCT
NCT04849910Phase 2Terminated
- Sponsor
- Vor Bio
- Start
- Dec 2021
- Primary completion
- May 2025
- Modality
- Gene Silencing, CRISPR-Cas9, Hematopoietic Stem Cells
- Countries
- 2
01
Overview
A Phase 2 trial of tremtelectogene empogeditemcel in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Vor Bio. Started Dec 2021; status: terminated.
02
Drugs
tremtelectogene empogeditemcel
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04849910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04849910.